Other · developed by Fresenius Kabi Usa
Omegaven is a 10% intravenous fish-oil lipid emulsion that supplies calories and essential fatty acids, which serve as substrates for energy production through beta oxidation and contribute to membrane structure and bioactive molecule synthesis. It is used as a source of nutrition in pediatric patients with parenteral nutrition-associated cholestasis and is also studied in critical illness.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Sep 5, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07883447 | Phase 2 | Critical Illness | Recruiting | FMS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Critical Illness
Updated Nov 8, 2026. Something wrong or missing? Report it on the FMS page.
See FMS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FMS catalysts and pipeline →